Subscription Center
Aug 18, 2008
On Friday, the U.S. Food and Drug Administration approved the first-ever treatment for Huntington's disease—the crippling illness that killed folksinger Woody Guthrie and that plagues 30,000 Americans.
Tetrabenazine, known commercially as Xenazine, was originally developed in the 1950s to treat symptoms of psychosis. It's not a cure-all for sufferers of the disease. Rather, it addresses a primary symptom of Huntington's—which is seen in 90 percent of patients: involuntary, spastic movements. According to a 2006 study, researchers at the University of Rochester Medical Center were able to reduce these movements in 54 patients by an average of 25 percent.
See what we're tweeting about
sciam Why Do Top Athletes Suddenly Develop the Yips --a Tendency to Choke under Pressure? http://t.co/3HBDnUjPi1 sciam Swiss Cheese and Dust Devils: 7 High-Resolution Shots of Surface Activity on Mars [Slide Show] http://t.co/Z0ABMm7Lih
johnrplatt Deadly Snakes, Ugly Critters, Leonardo DiCaprio and Other Links from the Brink | Extinction Countdown http://t.co/pbQGYG5G26
Deadline: Jun 30 2013
Reward: $1,000,000 USD
This is a Reduction-to-Practice Challenge that requires written documentation and&
Deadline: Jun 29 2013
Reward: $7,000 USD
The Seeker for this Challenge desires proposals for chemical methods that could rapidly degrade a dilute aqueous solution
Powered By: 
YES! Send me a free issue of Scientific American with no obligation to continue the subscription. If I like it, I will be billed for the one-year subscription.
